title: Preventing intraperitoneal adhesions with atorvastatin and sodium hyaluronate/carboxymethylcellulose: a comparative study in rats.
abstract: OBJECTIVE
  The aim of this study was to compare the effectiveness of atorvastatin with the sodium hyaluronate/carboxymethylcellulose (HA/CMC, Seprafilm; Genzyme; Genzyme Biosurgery Corporation, Cambridge, MA) in preventing postoperative intraperitoneal adhesion formation in rats.
  
  
  METHODS
  Sixty Wistar rats underwent a laparotomy, and adhesions A were induced by cecal abrasion. The animals were divided into 4 groups: group 1, control A; group 2, (A + atorvastatin); group 3, (A + HA/CMC), and group 4, (A + atorvastatin + HA/CMC). The atorvastatin (groups 2 and 4) and HA/CMC (groups 3 and 4) were administered intraperitoneally before the abdominal wall was closed. After 14 days, adhesions were classified by 2 independent surgeons.
  
  
  RESULTS
  The adhesion scores (mean +/- standard deviation) for groups 1, 2, 3, and 4 were 2.93 +/- .59, 1.85 +/- 1.07, 1.80 +/- .86, and 1.93 +/- .70, respectively. The differences in adhesion scores among all 3 preventive groups (groups 2, 3, and 4) were statistically significant when compared with the control group (P = .005, P = .002, and P = .009, respectively).
  
  
  CONCLUSIONS
  These data suggest that atorvastatin, administered intraperitoneally, is as effective as HA/CMC without an expectable additive effect in preventing postoperative adhesions in rats.
authors.affiliation: Second Propedeutical Department of Surgery, Aristotle University, Medical School, Hippokration Hospital, 49 Konstantinoupoleos Str., Thessaloniki, Greece. miltiadislalountas@yahoo.gr
authors.forename: Miltiadis A
authors.initials: MA
authors.lastname: Lalountas
authors.forename: Konstantinos D
authors.initials: KD
authors.lastname: Ballas
authors.forename: Christos
authors.initials: C
authors.lastname: Skouras
authors.forename: Christos
authors.initials: C
authors.lastname: Asteriou
authors.forename: Theodoros
authors.initials: T
authors.lastname: Kontoulis
authors.forename: Dimitrios
authors.initials: D
authors.lastname: Pissas
authors.forename: Apostolos
authors.initials: A
authors.lastname: Triantafyllou
authors.forename: Athanasios K
authors.initials: AK
authors.lastname: Sakantamis
mesh_terms: D000818:Animals; D000069059:Atorvastatin; D003131:Combined Modality Therapy; D006538:Heptanoic Acids / Q000008:administration & dosage / Q000627:therapeutic use*; D006820:Hyaluronic Acid; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D007274:Injections, Intraperitoneal; D007813:Laparotomy / Q000009:adverse effects*; D008297:Male; D010532:Peritoneal Diseases / Q000209:etiology / Q000473:pathology / Q000517:prevention & control*; D011758:Pyrroles / Q000008:administration & dosage / Q000627:therapeutic use*; D051381:Rats; D017208:Rats, Wistar; D000267:Tissue Adhesions / Q000209:etiology / Q000473:pathology / Q000517:prevention & control*
chemical_list: D006538:Heptanoic Acids; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D011758:Pyrroles; C118198:Seprafilm; D006820:Hyaluronic Acid; D000069059:Atorvastatin